4.0 Article

An Approach to Validating Criteria for Proteinuric Flare in Systemic Lupus Erythematosus Glomerulonephritis

期刊

ARTHRITIS AND RHEUMATISM
卷 63, 期 7, 页码 2031-2037

出版社

WILEY
DOI: 10.1002/art.30345

关键词

-

资金

  1. NIH [U01-DK-48621, P01-DK-55546]
  2. National Center for Research Resources [UL1-RR-025755]
  3. James D. Casto Research Fund

向作者/读者索取更多资源

Objective. Published criteria on the degree of proteinuria increase that defines a proteinuric flare in systemic lupus erythematosus (SLE) with glomerulonephritis (GN) vary widely, likely because they are not evidence based, but are largely based on expert opinion. Ideally, the threshold for proteinuric flare should be set sufficiently high that spontaneous variation in proteinuria does not likely explain the increase, but not so high that the patient needlessly experiences prolonged severe proteinuria before a flare is declared and therapy is increased. The present study was undertaken to develop an evidence-based approach to setting the threshold for proteinuric flare, based on quantifying the spontaneous variation in the urine protein:creatinine ratio in SLE GN patients who are not experiencing SLE flare. Methods. SLE GN patients (n = 71) in the Ohio SLE Study were tested at prespecified bimonthly intervals within windows of +/- 1 week. The median duration of followup was >44 months, and the rate of visit compliance was >90%. To assess spontaneous variation in the protein:creatinine ratio under no-flare conditions, we excluded protein:creatinine ratios measured within 4 months before or after renal flare. Results. Our findings showed that in the group of SLE GN patients with a mean no-flare protein: creatinine ratio of <= 0.5, the published flare thresholds are set well above the 99% confidence interval of the no-flare protein:creatinine ratio. The opposite was seen in the group with a mean no-flare protein:creatinine ratio of >= 1.0. Conclusion. Current thresholds for defining proteinuric flare appear to be set either too high or too low. A randomized trial would be needed to test whether resetting the thresholds would result in faster remission, reduction in therapy, and decrease in the frequency of chronic kidney disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据